Literature DB >> 20420824

FGFR3 mutation affects cell growth, apoptosis and attachment in keratinocytes.

Christian Hafner1, Erica Di Martino, Eva Pitt, Thomas Stempfl, Darren Tomlinson, Arndt Hartmann, Michael Landthaler, Margaret Knowles, Thomas Vogt.   

Abstract

FGFR3 mutations have recently been identified in several benign epidermal skin lesions such as seborrheic keratosis, epidermal nevus and solar lentigo. The functional consequences of these mutations in human skin are as yet unknown. In this study we analyzed the functional effects of the most common FGFR3 mutation in benign skin tumors, the R248C FGFR3 hotspot mutation, in human HaCaT keratinocytes. The cells were stably transduced with either the R248C or wildtype FGFR3 IIIb cDNA using a retroviral vector system. FGFR3 mutant and wildtype cells showed similar growth rates at subconfluence. However, at confluence FGFR3 mutant keratinocytes revealed a significantly higher cell number than wildtype cells. Furthermore, FGFR3 mutant cells showed significantly lower levels of apoptosis and decreased attachment to fibronectin compared with FGFR3 wildtype cells. Expression of mutant FGFR3 did not alter migration and senescence. Microarray analysis revealed only a few differentially expressed genes between FGFR3 mutant and wildtype keratinocytes. Enhanced phosphorylation of ERK1/2 was observed in confluent R248C mutant HaCaT cells compared with wildtype keratinocytes. Our results suggest that an increased cell number at confluence along with a decreased apoptosis may contribute to the development of acanthotic tumors in FGFR3 mutant skin in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20420824     DOI: 10.1016/j.yexcr.2010.04.021

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  11 in total

1.  Systemic epidermal nevus with involvement of the oral mucosa due to FGFR3 mutation.

Authors:  Anette Bygum; Christina R Fagerberg; Ole J Clemmensen; Britta Fiebig; Christian Hafner
Journal:  BMC Med Genet       Date:  2011-06-05       Impact factor: 2.103

2.  [R248C FGFR3 mutation. Effect on cell growth, apoptosis and attachment in HaCaT keratinocytes].

Authors:  C Hafner; A Hartmann
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

3.  Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors.

Authors:  Christian Hafner; Agustí Toll; Alejandro Fernández-Casado; Julie Earl; Miriam Marqués; Francesco Acquadro; Marinela Méndez-Pertuz; Miguel Urioste; Núria Malats; Julie E Burns; Margaret A Knowles; Juan C Cigudosa; Arndt Hartmann; Thomas Vogt; Michael Landthaler; Ramón M Pujol; Francisco X Real
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

Review 4.  [Genetic basis of seborrheic keratosis and epidermal nevi].

Authors:  C Hafner; H Hafner; L Groesser
Journal:  Pathologe       Date:  2014-09       Impact factor: 1.011

Review 5.  Mosaic RASopathies.

Authors:  Christian Hafner; Leopold Groesser
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

Review 6.  Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer.

Authors:  Tzuriel Sapir; David Shifteh; Moshe Pahmer; Sanjay Goel; Radhashree Maitra
Journal:  Mol Cancer Res       Date:  2020-12-07       Impact factor: 6.333

7.  Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.

Authors:  Baolai Zhang; Shuhong Dong; Ruiming Zhu; Chunyan Hu; Jing Hou; Yan Li; Qian Zhao; Xue Shao; Qian Bu; Hongyu Li; Yongjie Wu; Xiaobo Cen; Yinglan Zhao
Journal:  Oncotarget       Date:  2015-09-08

Review 8.  The Conundrum of Genetic "Drivers" in Benign Conditions.

Authors:  Shumei Kato; Scott M Lippman; Keith T Flaherty; Razelle Kurzrock
Journal:  J Natl Cancer Inst       Date:  2016-04-07       Impact factor: 13.506

9.  Fibroblast growth factor receptor 3 interacts with and activates TGFβ-activated kinase 1 tyrosine phosphorylation and NFκB signaling in multiple myeloma and bladder cancer.

Authors:  Lisa Salazar; Tamara Kashiwada; Pavel Krejci; April N Meyer; Malcolm Casale; Matthew Hallowell; William R Wilcox; Daniel J Donoghue; Leslie Michels Thompson
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

10.  Identification of a Novel Protein Arginine Methyltransferase 5 Inhibitor in Non-small Cell Lung Cancer by Structure-Based Virtual Screening.

Authors:  Qianqian Wang; Jiahui Xu; Ying Li; Jumin Huang; Zebo Jiang; Yuwei Wang; Liang Liu; Elaine Lai Han Leung; Xiaojun Yao
Journal:  Front Pharmacol       Date:  2018-03-01       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.